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inTROduCTiOn
Bisphosphonates (BPs) are selective inhibitors of os-
teoclast-mediated bone resorption. They promote
bone mineral secretion while at the same time con-
siderably reduce bone turnover by inducing osteoclast
apoptosis1-13. The first generation of non nitrogen-
containing BPs inhibit osteoclasts by inhibiting ATP-
dependent enzymes and the nitrogen-containing BPs
by inhibiting the Farnesyl Diphosphate (FPP) syntha -
se14,15. They are absorbed not only into active bone
mineral surfaces but also into other cell types such as
macrophages, epithelial, endothelial cells, circulating
monocytes and neoplastic cells14,15.
Long-term bisphosphonate use is associated with
adverse gastrointestinal effects. Specifically, adverse
events of the gastrointestinal tract include abdominal
pain, epigastric pain, nausea, dyspepsia, vomiting,
constipation, diarrhea, bleeding, esophageal ulceration,
esophagitis, esophageal erosions, esophageal adenocar -
cinoma, Barrett’s esophagus, gastric ulcer, cancer of
gastrointestinal tract and hepatotoxicity4,5,7,11, 12,14-
21. In general, bisphosphonates are poorly absorbed
by the gastrointestinal tract as a result of their poor
li pophilicity1. Oral bioavailability is about 0.9 to
1.8%2,3,22 leading to very low peak values in the plas-
ma22. Systemically available bisphosphonates disappear
very rapidly from plasma, and they are either taken
up by bone tissues or excreted by the kidneys which
is the only route of elimination1,2,3. Renal clearance
appears to involve both glomerular filtration and an
especially secretory pathway3. To date, all bisphos-
phonates studied show no evidence of metabolism1.
The drug which is not excreted within 24 hours after
dosing is believed to be sequestered in the skeleton.
Afterwards, it is released slowly into the circulation
until to be eliminated from the kidneys2. The elimi-
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nation from bone tissue is slow, ranging from 200 days
in rats to 12 years in humans2. The bone (tibia) con-
tains the highest concentration of all tissues24 and the
disposition of the BPs in soft tissues (liver, kidney and
spleen) is dependent on route and rate of drug ad-
ministration and the osmolality of the vehicle23,24,25.
In our report, we have studied the effects of bis-
phosphonate use on liver. In liver, bisphosphonate
use has been associated with hepatotoxicity confirmed
by liver biopsy, severe acute hepatitis and chronic
hepatitis. However, data concerning the side effects
of BP use on the liver, are still limited.15, 26-30
MATeRiAlS And MeThOdS
This study was approved by the Bioethics Committee
of the Medical School of the Aristotle University of
Thessaloniki. Twenty female Wistar rats, 12-month
old, weighing approximately 500 g, were used in the
experiment. Rats were housed in stainless steel cages,
with one rat per cage, 12h light-dark cycle and relative
humidity and temperature control.
The animals were randomly allocated into two
groups: Group A, the experimental group, that con-
sisted of 10 animals, and Group B, the control group,
that also consisted of 10 animals. Alendronate (Fos-
amax, Merck) was administered per os to animals of
Group A at a dose of 0.05 mg/kg body weight/week
dissolved in 3cc normal saline for a period of 13 weeks,
as previously described. The drug was administered
thirty minutes prior to breakfast. The dose was cal-
culated according to the usual human dose31,32. The
duration of the study was limited to 13 weeks and
after euthanasia, the liver of the animals was removed
and specimens were processed for electron microscopy
examination.
Transmission electron Microscopy
Liver tissue samples were sectioned into <1cm3 pieces.
They were placed into glutaraldehyde 3% for 2 hours,
followed by 1 hour into osmium tetroxide (OsO4) 1%.
Staining was performed with uranyl acetate 1% for
16 hours and then samples were dehydrated with in-
creased ethanol concentrations. Samples were em-
bedded into Epon resin and ultra-thin sections (60-
90 nm) were taken. Finally, sections were stained with
Reynolds’s stain. Samples were observed under a
TEM JEOL 1011.
ReSulTS
Electron microscopy examination did not reveal patho-
logic changes within the hepatocytes of the control
group, however the presence of significant amount
glycogen was observed. It was also found that the s-
mooth endoplasmic reticulum, the lysosomes, the s-
inusoids, the space of Disse as well as the bile canalicu-
lus were normal (Fig. 1).
In the experimental group, evidence of mild dys-
function of the hepatic cells was found in all sections
and there was an extensive depletion of the glycogen
in the hepatocytes (Fig. 2). Dilated sinusoids (Fig. 3)
and increased number of vacuoles in the cytoplasm
has also been seen. Moreover, the microvilli of hep-
atocytes on the Disse’s space surface were missing in
many areas (Fig. 3) and finally, collagen fibers were
detected in extracellular matrix (Fig. 4). 
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Figure 1: Control group. S: sinusoid, mv: microvilli, H: he -
pa tocytes, g: glycogen.
Figure 2: Experimental Group. Depletion of glycogen (á),
vacuoles (v), nucleus of hepatocyte (n).
diSCuSSiOn
Bisphosphonates are selective inhibitors of osteoclast
mediated bone resorption and they are used for the
treatment of bone disorders as well as for tumors.
Their adverse effects have been studied and reported
in many previous studies and case reports. Our report
tries to elucidate the possible effects of BPs in hepatic
structure and consequently in hepatic function.
In various case reports, alendronate has been as-
sociated with hepatic dysfunction26,27,29. Besides al-
endronate, there were other bisphosphonate drugs
associated with hepatic dysfunction or lesion33-37,15.
According to Lieverse et al (1998), alendronate med-
ication was the cause of severe hepatitis in a 77 year-
old woman as no other obvious cause was found and
the hepatitis resolved after alendronate was no longer
administered28. Furthermore, Halabe et al (2000),
reported that alendronate may affect liver function,
by inhibiting hepatic synthesis of cholesterol. However,
the histologic findings suggested that the patient had
inflammatory, rather than toxic liver injury30. Our
study agrees with previous reports, as the histological
findings in our research indicate mild hepatic damage
(extensive depletion of the glycogen, dilated sinusoids
and increase number of vacuoles, and absence of mi-
crovilli in the peri-sinusoidal space). According to
Panebianco et al (2016), hepatic stellate cells (HSCs),
also known as perisinusoidal cells, are pericytes found
in the perisinusoidal space of the liver and are the
major cell type involved in liver fibrosis. Liver fibrosis
is the formation of scar tissue in response to liver
damage. When liver is damaged, stellate cells can shift
into an activated state and secrete collagen scar tissue,
which can lead to cirrhosis. Therefore, the presence
of collagen in the extracellular matrix may indicate
hepatic damage41. A correlation seems to exist between
alendronate administration and hepatic cell dysfunc-
tion. Conclusively, bisphosphonate use may be the
cause of hepatic damage38-41.
Our study demonstrates a possible effect of alen-
dronate administration on liver’s function and mor-
phology. As far as we know, our study is the only one
in the literature that examines the possible effects of
bisphosphonate use in hepatic tissue by electron mi-
croscope. However, there were limitations, such as
the small number of animals and the short-term ad-
ministration of the drug due to the fast accumulation
of alendronate in bone tissue1. Further research is
needed, in order to detect the possible effect of bis-
phosphonate drugs in hepatic cell function and also
the mechanisms of action.
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Figure 3: Experimental Group. Extensive depletion of gly -
cogen (á). Absence of microvilli in the space of Disse (*).
Dilated sinusoids.
Figure 4: Experimental Group. Presence of collagen in ex-
tracellular matrix (á). Sinusoids (S). Absence of microvilli
in the space of Disse (*).
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Η επίδραση των διφωσφονικών στα  ηπατικά κύτταρα ποντικιών: 
Μελέτη με ηλεκτρονικό μικροσκόπιο
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ΠερiλΗψΗ: Σκοπός: Τα διφωσφονικά αποτελούν εκλεκτικούς αναστολείς της οστικής απορρόφησης και η μακροχρόνια
χρήση τους έχει συσχετισθεί με ανεπιθύμητες επιδράσεις στο γαστρεντερικό σύστημα. Σκοπός της εργασίας είναι η
διερεύνηση των πιθανών επιδράσεων των διφωσφονικών στη δομή των ηπατικών κυττάρων. Υλικά και μέθοδος: Ελήφθησαν
δείγματα ηπατικού ιστού από δέκα θηλυκά ποντίκια Wistar ηλικίας δώδεκα μηνών που έλαβαν Αλενδρονάτη από του
στόματος για 13 εβδομάδες και από δέκα θηλυκά ποντίκια Wistar ηλικίας δώδεκα μηνών που δεν έλαβαν το φάρμακο και
χρησιμοποιήθηκαν ως μάρτυρες. Τα δείγματα μελετήθηκαν με το ηλεκτρονικό μικροσκόπιο. Αποτελέσματα: Στα ηπατικά
κύτταρα των ποντικιών που έλαβαν Αλενδρονάτη βρέθηκαν εκτεταμένη απώλεια γλυκογόνου, διαφόρου μεγέθους κενοτόπια,
διευρυμένα κολπώδη τριχοειδή, καθώς και απουσία των μικρολαχνών σε πολλά σημεία του χώρου του Disse. Συμπέρασμα:
Πρόκειται για την πρώτη μελέτη με ηλεκτρονικό μικροσκόπιο ηπατικών δειγμάτων μετά τη χορήγηση διφωσφονικών, η
οποία υποδεικνύει ήπια ηπατική βλάβη. Μια πιθανή συσχέτιση μεταξύ της χρήσης της Αλενδρονάτης και της ηπατικής
λειτουργίας καθίσταται εμφανής. Ωστόσο, εξαιτίας του μικρού αριθμού δειγμάτων περισσότερες μελέτες είναι απαραίτητες
ώστε να διαλευκανθεί αυτή η συσχέτιση.
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